KEYTRUDA may be used, but is not funded, in adults and children with classical Hodgkin lymphoma that has returned or when other treatments have not worked.
KEYTRUDA may be used, but is not funded, in certain adults and children with colorectal cancer that is shown by a laboratory test to be MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient), and that has spread or cannot be removed by surgery.
KEYTRUDA® may be used, but is not funded, in patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.
KEYTRUDA may be used, but is not funded, in certain adults with head and neck squamous cell carcinoma that has spread or returned and cannot be removed by surgery.
KEYTRUDA is funded (restrictions apply), in adults with melanoma that has spread or cannot be removed by surgery. KEYTRUDA may be used, but is not funded, in certain adults and children with melanoma given after surgery to prevent the cancer from coming back.
KEYTRUDA may be used, but is not funded, in certain adults and children with a kind of cancer that can occur in any part of the body and is shown by a laboratory test to be MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient), and that has spread or cannot be removed by surgery.
KEYTRUDA is funded (restrictions apply) for the treatment of certain patients with non-small cell lung cancer (NSCLC) which has spread (metastatic), or is advanced and cannot be removed by surgery. KEYTRUDA may be used, but is not funded, in adults with certain types of early stage NSCLC, given after surgery to prevent the cancer from coming back.
KEYTRUDA may be used, but is not funded, in adults with cancer of the oesophagus or gastroesophageal junction that has spread or cannot be removed by surgery.
KEYTRUDA may be used, but is not funded, in adults with renal cell carcinoma that has spread or cannot be removed by surgery, or in adults with certain types of renal cell carcinoma, given after surgery to prevent the cancer from coming back.
KEYTRUDA may be used, but is not funded, in certain adults with triple-negative breast cancer (TNBC) that has returned and cannot be removed by surgery, or has spread; or in adults with certain types of early stage TNBC given before surgery and then continued after surgery to help prevent the cancer from coming back.
KEYTRUDA may be used, but is not funded, in certain adults with urothelial carcinoma that has spread or cannot be removed by surgery, or in certain adults with bladder cancer which has not spread to nearby tissues but is at high-risk of spreading and where bladder removal is not preferred.
The information on this website should be discussed with your healthcare professional and does not replace their advice.
References:
KEYTRUDA Data Sheet
Cancer Council Australia. 2021. Understanding Immunotherapy. A guide for people affected by cancer.
Available at: https://www.cancer.org.au/assets/pdf/understanding-immunotherapy-fact-sheet
Accessed on 02/06/2023
KEYTRUDA Consumer Medicine Information
NZ-KEY-00863. TAPS DA 2339KN TAPS NP20132. First Issued February 2024.
You are leaving the Fight Cancer website
You are leaving the Fight Cancer website. By continuing, you will be directed to another website, which MSD New Zealand has not developed. This website may not be consistent with the New Zealand legislation or advertising codes. We do not review or control the content of this website. We do not endorse and are not responsible for the accuracy, content, practices, or standards of any linked websites.